CP and chronic myelogenous leukemia, BCR-ABL1 positive: Asciminib is also approved by the Ministry of Health, Labour, and Welfare in Japan for the treatment of CML patients with resistance or intolerance to previous TKI therapy in March 2022, followed by the approval by the European Medicines Agency for the treatment of adult patients with Ph + CML-CP previously treated with ≥ 2 TKIs in August 2022.